Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Our specialist services

Adaptive Phase I & II
Adaptive Phase III
TQT Studies
Bridging Studies
Patient Recruitment
Data Management
Gene Editing & Gene Silencing
Regulatory Strategy Services
Pharmacovigilance

サービス一覧

適応的第I相・第II相試験
適応的第III相試験
TQT試験（心電図QT間隔評価試験）
ブリッジング試験
被験者リクルートメント
データマネジメント
遺伝子編集・遺伝子サイレンシング
規制戦略サービス
ファーマコビジランス
YOU ARE HERE: HOME > NEWS

Local volunteers play valuable role in developing new medicines in Croydon

21
March 2014

View Article

Richmond Pharmacology presents latest Thorough QT study at the ASCPT 2014 Annual Meeting

3
March 2014

View Article

AGAH Annual Meeting 2014 Mitigating risks in early medicines development

10
January 2014

View Article

A volunteer panel the size of a city...

21
November 2013

View Article

Richmond Pharmacology presents latest Thorough QT study at the ASCPT 2014 Annual Meeting

3
March 2013

Moxifloxacin is used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. A meal shortens the QT interval and in some instances it is desirable to use moxifloxacin after a meal which may affect PK or PD or both; however there is no published data.

View Article

Joint Conference of European Human Pharmacological Societies CLUB PHASE I (France), AGAH (Germany), BAPU (Belgium), AHPPI (UK)

28
February 2013

View Article

Meet the experts

Meet the leadership team and scientific experts behind Richmond Pharmacology's clinical research excellence.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read more

Upcoming Event

ESC Congress 2026

28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event
© 2026 Richmond Pharmacology - all rights reserved
Disclaimer
|
Sitemap
|
Privacy Policy
|
Report A Concern
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesRejectAccept